Live presentation DDW 2022: AI and Precision Medicine in Ulcerative Colitis
Join Dr Olga Kubassova, IAG’s CEO, Simon Hart, IAG’s Bio-partnering Director, and key opinion leader Professor Laurent Peyrin-Biroulet (Nancy University Hospital, France) during a live presentation of our collaborative project with Takeda Pharmaceuticals International AG.
“An Artificial Intelligence driven scoring system to measure histological disease activity in Ulcerative Colitis”
Date: 24 May 2022, 2:30 pm PDT
In this live presentation, Professor Laurent Peyrin-Biroulet will discuss the application of IAG’s Artificial Intelligence (AI) driven assessment of histopathology ulcerative colitis images, in the first of a series of collaborative projects between IAG and Takeda.
Join IAG at the presentation, or if you are not attending, schedule a call: firstname.lastname@example.org
About the project
The collaboration is supported by prominent clinical centres and opinion leaders, including sites in Switzerland, France, Canada, USA, Israel, and Portugal.
IAG and Takeda have been working together since 2019 and have developed a novel Artificial Intelligence (AI)-powered method for the assessment of histopathology ulcerative colitis images. The tool will potentially allow practising gastroenterologists to evaluate disease activity with an automated method that is accurate, reproducible and reliable in UC patients. To date, the AI Tool has been trained and tested on 200 images, showing performance comparable to a human expert. As the next step, the partners are engaging eight world-leading sites, who will test the AI Tool in their clinical practices.
‘Together with our commercial and academic partners, we are excited to be in the position to advance clinical decision-making by bringing better technologies into the play’, said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.
‘Augmenting clinical decision-making with AI in the field of histopathology has the potential to bring great value for management of patients with ulcerative colitis. Our AI Tool’s ability to provide additional information on the disease state and patient response to a new treatment in real-time gives us ability to gain more insights and make better and faster decisions,’ said Prof. Laurent Peyrin-Biroulet, Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy.
“As part of our 30-year commitment to gastroenterology, we recognize the importance of collaborations with digital health leaders, such as IAG, to identify and pursue cutting edge technologies to advance the care of patients. We see great potential in this initiative and are excited to enter into the next phase of research using deep learning models and AI to support gastroenterologists’ in their patient care”, said Dr. Shashi Adsul, Sr. Director, Global Medical Unit Head at Takeda Pharmaceuticals International AG.
Digestive Disease Week (DDW) is the most prestigious meeting in the world for GI professionals providing an unparalleled opportunity to delve into exciting new developments with leaders in gastroenterology, hepatology, endoscopy and gastrointestinal surgery. To find out more about this conference click here.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.